Contact

Factor X Deficiency

Research

Research/IND Treatment Protocols

Bio Products Laboratory (BPL) is currently sponsoring 3 clinical trials to study BPL’s high-purity, plasma-derived FX product Coagadex® in certain clinical settings-

  1. A study to investigate BPL’s factor X in the prophylaxis of bleeding in children <12 years; Available from: https://clinicaltrials.gov/ct2/show/NCT01721681
  2. Data collection to investigate compassionate use with FACTOR X: a multicenter, retrospective data collection study on the use of BPL’s high purityfactor X in the treatment of patients with hereditary factor X deficiency: National Health Service Health Research Authority – Ten05; Available from: http://www.hra.nhs.uk/news/research-summaries/data-collection-to-investigate-compassionate-use-with-factor-x/
  3. Post-marketing registry of use of Coagadex® for surgical procedures – US Food and Drug Administration. Biologics license application approval for coagulation factor X (human); Available from: https://www.fda.gov/download/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM468124.pdf

Acknowledgment

Rare Coagulation Disorders Resource Room, an extension of the RBDD Registry (eu.rbdd.org), was developed in collaboration with the Indiana Hemophilia & Thrombosis Center (www.innovativehematology.org).

The Resource Room serves as a platform to promote international collaboration to increase knowledge of these very rare disorders and to improve the care of affected individuals. The international RBDD mission, under the leadership of Dr. Peyvandi, will continue to be expanded over time.

The Resource Room thanks all contributing authors of the website articles that have made this valuable information available to the global community of both individuals affected with rare coagulation disorders and their healthcare providers.

A collaboration of RBDD & IHTC

Quick Links